Nanocomposites have emerged as promising materials in cancer diagnosis and treatment due to their unique properties that enhance sensitivity, specificity, and imaging resolution. These materials combine nanoparticles with polymers or other matrix materials, allowing for targeted delivery, imaging, and therapeutic interventions. Nanocomposites can be designed to detect cancer biomarkers, improve diagnostic accuracy, and deliver therapeutic agents with enhanced bioavailability and reduced toxicity. They are used in various applications, including imaging agents, biosensors, and drug delivery systems. The integration of different imaging modalities, such as MRI, CT, and fluorescence imaging, into nanocomposites enables the development of contrast agents with enhanced sensitivity and specificity. Functionalizing nanocomposites with targeting ligands ensures selective accumulation in tumor tissues, facilitating precise imaging and diagnostic accuracy. On the therapeutic front, nanocomposites have revolutionized cancer treatment by overcoming traditional challenges associated with drug delivery. The controlled release of therapeutic agents from nanocomposite carriers enhances drug bioavailability, reduces systemic toxicity, and improves overall treatment efficacy. Additionally, the integration of stimuli-responsive components within nanocomposites enables site-specific drug release triggered by the unique microenvironment of the tumor. Despite the remarkable progress in the field, challenges such as biocompatibility, scalability, and long-term safety profiles remain. This article provides a comprehensive overview of recent developments, challenges, and prospects, emphasizing the transformative potential of nanocomposites in revolutionizing the landscape of cancer diagnostics and therapeutics. In conclusion, integrating nanocomposites in cancer diagnosis and treatment heralds a new era for precision medicine. Keywords: nanocomposites, cancer, diagnosis, therapy, nanoparticles, theranostic.Nanocomposites have emerged as promising materials in cancer diagnosis and treatment due to their unique properties that enhance sensitivity, specificity, and imaging resolution. These materials combine nanoparticles with polymers or other matrix materials, allowing for targeted delivery, imaging, and therapeutic interventions. Nanocomposites can be designed to detect cancer biomarkers, improve diagnostic accuracy, and deliver therapeutic agents with enhanced bioavailability and reduced toxicity. They are used in various applications, including imaging agents, biosensors, and drug delivery systems. The integration of different imaging modalities, such as MRI, CT, and fluorescence imaging, into nanocomposites enables the development of contrast agents with enhanced sensitivity and specificity. Functionalizing nanocomposites with targeting ligands ensures selective accumulation in tumor tissues, facilitating precise imaging and diagnostic accuracy. On the therapeutic front, nanocomposites have revolutionized cancer treatment by overcoming traditional challenges associated with drug delivery. The controlled release of therapeutic agents from nanocomposite carriers enhances drug bioavailability, reduces systemic toxicity, and improves overall treatment efficacy. Additionally, the integration of stimuli-responsive components within nanocomposites enables site-specific drug release triggered by the unique microenvironment of the tumor. Despite the remarkable progress in the field, challenges such as biocompatibility, scalability, and long-term safety profiles remain. This article provides a comprehensive overview of recent developments, challenges, and prospects, emphasizing the transformative potential of nanocomposites in revolutionizing the landscape of cancer diagnostics and therapeutics. In conclusion, integrating nanocomposites in cancer diagnosis and treatment heralds a new era for precision medicine. Keywords: nanocomposites, cancer, diagnosis, therapy, nanoparticles, theranostic.